Genolution 2026 Q1: Revenue Surges 42%, Net Profit Swings to Black

Consolidated Q1 revenue 2,486M KRW (separate 2,407M KRW), up 42% YoY
Operating loss narrowed to 1,382M (consolidated) and 1,076M (separate), vs. 2,068M loss in prior year Q1
Net profit turned positive: 440M (consolidated) and 738M (separate), vs. loss of 2,254M in prior year Q1
Debt-to-equity ratio stable at 38% (consolidated) and 37% (separate)\- Cash equivalents 18,217M (consolidated); borrowings 23,830M (separate)
R&D expenses 124M (consolidated) and 120M (separate)
Treasury shares: 1,112,906 shares (5.8%); stock grant of 10,545 shares exercised
New patents acquired including dsRNA for pine wilt disease; total 23 intellectual property rights